US Bancorp DE grew its position in Codexis, Inc. (NASDAQ:CDXS – Get Rating) by 21.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,586 shares of the biotechnology company's stock after purchasing an additional 2,540 shares during the quarter. US Bancorp DE's holdings in Codexis were worth $89,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Strs Ohio grew its position in shares of Codexis by 237.6% in the third quarter. Strs Ohio now owns 36,800 shares of the biotechnology company's stock valued at $223,000 after purchasing an additional 25,900 shares during the last quarter. Versor Investments LP grew its position in shares of Codexis by 87.7% in the third quarter. Versor Investments LP now owns 27,300 shares of the biotechnology company's stock valued at $165,000 after purchasing an additional 12,758 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Codexis by 1.7% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,132,124 shares of the biotechnology company's stock valued at $6,861,000 after purchasing an additional 19,180 shares during the last quarter. Private Advisor Group LLC grew its position in shares of Codexis by 11.7% in the third quarter. Private Advisor Group LLC now owns 87,059 shares of the biotechnology company's stock valued at $528,000 after purchasing an additional 9,129 shares during the last quarter. Finally, Jackson Square Capital LLC acquired a new position in shares of Codexis in the third quarter valued at approximately $363,000. Institutional investors and hedge funds own 93.41% of the company's stock.

Insiders Place Their Bets

In other Codexis news, Director John J. Nicols sold 35,714 shares of the company's stock in a transaction on Tuesday, January 24th. The stock was sold at an average price of $6.42, for a total transaction of $229,283.88. Following the completion of the sale, the director now directly owns 823,750 shares in the company, valued at $5,288,475. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director John J. Nicols sold 35,714 shares of the stock in a transaction on Tuesday, January 24th. The stock was sold at an average price of $6.42, for a total value of $229,283.88. Following the completion of the transaction, the director now directly owns 823,750 shares in the company, valued at approximately $5,288,475. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John J. Nicols sold 39,785 shares of the stock in a transaction on Friday, December 9th. The shares were sold at an average price of $5.66, for a total value of $225,183.10. Following the completion of the transaction, the director now owns 863,535 shares of the company's stock, valued at $4,887,608.10. The disclosure for this sale can be found here. Insiders sold 111,213 shares of company stock worth $657,323 over the last three months. Insiders own 7.00% of the company's stock.

Analyst Ratings Changes

Codexis Price Performance

NASDAQ CDXS opened at $6.57 on Monday. The business has a fifty day moving average price of $5.47 and a two-hundred day moving average price of $6.32. Codexis, Inc. has a fifty-two week low of $4.21 and a fifty-two week high of $22.22. The stock has a market capitalization of $431.58 million, a PE ratio of -13.69 and a beta of 1.47.

Codexis (NASDAQ:CDXS – Get Rating) last released its earnings results on Thursday, November 3rd. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. Codexis had a negative return on equity of 19.59% and a negative net margin of 23.49%. The firm had revenue of $34.47 million during the quarter, compared to analysts' expectations of $31.41 million. As a group, sell-side analysts expect that Codexis, Inc. will post -0.56 earnings per share for the current year.

Codexis Profile

(Get Rating)

Codexis, Inc is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market.

Further Reading

• Get a free copy of the StockNews.com research report on Codexis (CDXS)
• Is Seagate Technology Signaling the End of its Normalization?
• eHealth Stock Rises from the Ashes. Time to Get In?
• Can Yext A.I. Search Platform Drive Growth in 2023?
• Cassava Sciences Stock Undervalued with Its $124 Price Target?
• Constellation Brands: Are Consumers Trading Down for Rail Drinks?

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.